In the murine models of KRAS-dependent lung cancer, WT1 deletion/suppression led to senescence only in KRAS-expressing cells, and did not impact wild-type cells, while WT1 loss determined reduction in tumor burden. This evidence concerns the gene KRAS and lung cancer.